20 related articles for article (PubMed ID: 38670553)
1. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
[TBL] [Abstract][Full Text] [Related]
2. Discoidin domain receptor 2 (DDR2) promotes breast cancer cell metastasis and the mechanism implicates epithelial-mesenchymal transition programme under hypoxia.
Ren T; Zhang W; Liu X; Zhao H; Zhang J; Zhang J; Li X; Zhang Y; Bu X; Shi M; Yao L; Su J
J Pathol; 2014 Dec; 234(4):526-37. PubMed ID: 25130389
[TBL] [Abstract][Full Text] [Related]
3. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J
Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243
[TBL] [Abstract][Full Text] [Related]
4. Discoidin domain receptor 2 facilitates prostate cancer bone metastasis via regulating parathyroid hormone-related protein.
Yan Z; Jin S; Wei Z; Huilian H; Zhanhai Y; Yue T; Juan L; Jing L; Libo Y; Xu L
Biochim Biophys Acta; 2014 Sep; 1842(9):1350-63. PubMed ID: 24787381
[TBL] [Abstract][Full Text] [Related]
5. NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy.
Xu C; Buczkowski KA; Zhang Y; Asahina H; Beauchamp EM; Terai H; Li YY; Meyerson M; Wong KK; Hammerman PS
Mol Cancer Ther; 2015 Oct; 14(10):2382-2389. PubMed ID: 26206333
[TBL] [Abstract][Full Text] [Related]
6. Neuroblastoma models for insights into tumorigenesis and new therapies.
Kiyonari S; Kadomatsu K
Expert Opin Drug Discov; 2015 Jan; 10(1):53-62. PubMed ID: 25345447
[TBL] [Abstract][Full Text] [Related]
7. Blockade of Discoidin Domain Receptor Signaling with Sitravatinib Reveals DDR2 as a Mediator of Neuroblastoma Pathogenesis and Metastasis.
Rozen EJ; Frantz W; Wigglesworth K; Vessella T; Zhou HS; Shohet JM
Mol Cancer Ther; 2024 Apr; ():. PubMed ID: 38670553
[TBL] [Abstract][Full Text] [Related]
8. Discoidin Domain Receptor 2: A New Target in Cancer.
Xu X; Yu T; Wang Z
Oncol Res Treat; 2022; 45(4):205-215. PubMed ID: 35073544
[TBL] [Abstract][Full Text] [Related]
9. Novel insights into the role of Discoidin domain receptor 2 (DDR2) in cancer progression: a new avenue of therapeutic intervention.
Trono P; Ottavi F; Rosano' L
Matrix Biol; 2024 Jan; 125():31-39. PubMed ID: 38081526
[TBL] [Abstract][Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
